Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GALR2 | O43603 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18979043 | 0.99 | ALDH1A1 (0.41) | ALDH1A1POLBNPSR1SMN1; SMN2GALR2 | |
| SCHEMBL17490479 | 0.88 | NPSR1 (0.40) | ALDH1A1POLBNPSR1SMN1; SMN2GALR2 | |
| SCHEMBL29866463 | 0.87 | NPSR1 (0.42) | ALDH1A1POLBNPSR1SMN1; SMN2GALR2 | |
| SCHEMBL18978915 | 0.86 | ALDH1A1 (0.40) | ALDH1A1POLBNPSR1SMN1; SMN2GALR2 | |
| SCHEMBL18978911 | 0.80 | KDM4E (0.38) | ALDH1A1POLBNPSR1SMN1; SMN2GALR2 | |
| SCHEMBL18978910 | 0.80 | KDM4E (0.38) | ALDH1A1POLBNPSR1SMN1; SMN2GALR2 | |
| SCHEMBL10745494 | 0.79 | POLB (0.49) | ALDH1A1POLBNPSR1SMN1; SMN2GALR2 | |
| SCHEMBL30467879 | 0.79 | EGFR (0.41) | — | |
| SCHEMBL19100747 | 0.79 | EGFR (0.41) | — | |
| SCHEMBL17339112 | 0.79 | SMN1; SMN2 (0.35) | ALDH1A1NPSR1SMN1; SMN2MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327402-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| CN-115836064-B | Triazine derivative with EGFR (epidermal growth factor receptor) inhibition activity as well as preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-RE49851-E1 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2024-02-27 | — | — | US | disclosed |
| US-RE49851-E1 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2024-02-27 | — | — | US | disclosed |
| US-RE49851-E1 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2024-02-27 | — | — | US | disclosed |
| CN-112292378-B | Indole derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-117440945-A | Pyrimidine or pyridine derivative, preparation method thereof and application thereof in pharmacy | 上海和誉生物医药科技有限公司 | 2024-01-23 | — | — | CN | disclosed |
| EP-4257584-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| EP-3492462-B1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-3492462-B1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-3181560-B1 | PYRIDINE AMIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | SHANGHAI ALLIST PHARMACEUTICALS CO LTD (CN) | 2020-11-25 | — | — | EP | disclosed |
| EP-3492462-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | Shenzhen Targetrx, Inc. (CN) | 2019-06-05 | — | — | EP | disclosed |
| US-20190152954-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-10072002-B2 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2018-09-11 | — | — | US | disclosed |
| US-20170210739-A1 | PYRIDINYLAMINOPYRIMIDINE DERIVATIVES, PREPARATION PROCESS AND USE THEREOF | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2017-07-27 | — | — | US | disclosed |
| US-20170210739-A1 | PYRIDINYLAMINOPYRIMIDINE DERIVATIVES, PREPARATION PROCESS AND USE THEREOF | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2017-07-27 | — | — | US | disclosed |
| US-20170210739-A1 | PYRIDINYLAMINOPYRIMIDINE DERIVATIVES, PREPARATION PROCESS AND USE THEREOF | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2017-07-27 | — | — | US | disclosed |
| EP-3181560-A1 | PYRIDINE AMIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Shanghai Allist Pharmaceuticals, Inc. (CN) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181560-A1 | PYRIDINE AMIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Shanghai Allist Pharmaceuticals, Inc. (CN) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016015453-A1 | PYRIDINE AMIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | 上海艾力斯医药科技有限公司 | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327402-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY | WEE1, WEE2, EGFR | ALDH1A1 1967/4885POLB 1125/4885NPSR1 4246/4885 |
| US-20170210739-A1 | PYRIDINYLAMINOPYRIMIDINE DERIVATIVES, PREPARATION PROCESS AND USE THEREOF | EGFR, ERBB2, ERBB4 | ALDH1A1 961/4885POLB 1842/4885NPSR1 1035/4885 |
| US-20190152954-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | LCK, WEE1, JAK1 | ALDH1A1 3601/4885POLB 2725/4885NPSR1 1406/4885 |
| US-10072002-B2 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | EGFR, ERBB2, ERBB4 | ALDH1A1 961/4885POLB 1842/4885NPSR1 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.